Eldecalcitol: newly developed active vitamin D₃ analog for the treatment of osteoporosis

Bibliography

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   PubMed Web of Science ®Google Scholar
• Felsenberg D, Bock O, Borst H, Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass. J Musculoskelet Neuronal Interact 2011;11:34-45
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Willett WC, Orav EJ, A pooled analysis of vitamin D dose requirements for fracture prevention. N Eng J Med 2012;367:40-9
   PubMed Web of Science ®Google Scholar
• Papadimitropoulos E, Wells G, Shea B, Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-9
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Willett WC, Wong JB, Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64
   PubMed Web of Science ®Google Scholar
• Richy F, Schacht E, Bruyere O, Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005;76:176-86
   PubMed Web of Science ®Google Scholar
• Sanford M, McCormack PL. Eldecalcitol: a review of its use in the treatment of osteoporosis. Drugs 2011;71:1755-70
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Murayama E, Ochi K, Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2beta-position. Chem Pharm Bull 1993;41:1111-13
   PubMed Web of Science ®Google Scholar
• Uchiyama Y, Higuch Y, Takeda S, ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002;30:582-8
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Nagashima S, Imai N, Synthesis and biological evaluation of a 3-positon epimer of 1alpha,25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71). J Steroid Biochem Mol Biol 2007;103:222-6
   PubMed Web of Science ®Google Scholar
• Furuichi T, Kawata S, Asoh Y, Differential time course of induction of 1alpha,25-dihydroxyvitamin D3-24-hydroxylase mRNA expression in rats by 1alpha,25-dihydroxyvitamin D3 and its analogs. Life Sci 1998;62:453-9
   PubMed Web of Science ®Google Scholar
• Ritter CS, Brown AJ. Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism. J Cell Biochem 2011;112:1348-52
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Takano T, Yamakido S, Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol 2010;121:261-4
   PubMed Web of Science ®Google Scholar
• Abe M, Tsuji N, Takahashi F, Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D3 derivative. Jpn Pharmacol Ther 2011;39:261-74
   Google Scholar
• Harada S, Takeda S, Uno A, Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J Steroid Biochem Mol Biol 2010;121:281-3
   PubMed Web of Science ®Google Scholar
• Saito H, Harada S, Takahashi F. Active vitamin D3 inhibits bone resorption in vivo. Med Sci Digest 2011;37:111-15
   Google Scholar
• Sakai S, Takaishi H, Matsuzaki K, 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 2009;27:643-52
   PubMed Web of Science ®Google Scholar
• Ueno Y, Shinki T, Nagai Y, In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003;90:267-77
   PubMed Web of Science ®Google Scholar
• de Freitas PH, Hasegawa T, Takeda S, Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 2011;49:335-42
   PubMed Web of Science ®Google Scholar
• Harada S, Kobayashi Y, Nakamichi Y, Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2012;27:461-73
   PubMed Web of Science ®Google Scholar
• Tsurukami H, Nakamura T, Suzuki K, A novel synthetic vitamin D analogue, 2beta-(3-hydroxypropoxy)1alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 1994;54:142-9
   PubMed Web of Science ®Google Scholar
• Saito H, Takeda S, Amizuka N. Eldecalcitol and calcitriol stimulates ‘bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol 2012; published online 13 October 2006; doi:10.1016/j.jsbmb.2012.10.004
   Web of Science ®Google Scholar
• Kobayashi S, Takahashi HE, Ito A, Trabecular minimodeling in human iliac bone. Bone 2003;32:163-9
   PubMedGoogle Scholar
• Ochi H. 2beta-(3-Hydroxypropoxy)-1alpha,25-Dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating bone formation in hypophosphatemic mice. J Okayama Medical Association 1998;110:31-7
   Google Scholar
• Brown AJ, Ritter CS. The vitamin D analog 1alpha,25-Dihydroxy-2beta-(3-Hydroxypropyloxy) vitamin D3 (Eldecalcitol) is a potent regulator of calcium and phosphate metabolism. Calcif Tissue Int 2011;89:372-8
   PubMed Web of Science ®Google Scholar
• Yamane K, Okano T, Kishimoto H, Effect of ED-71 on modeling of bone in distraction osteogenesis. Bone 1999;24:187-93
   PubMed Web of Science ®Google Scholar
• Cao Y, Mori S, Mashiba T, 1alpha,25-Dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71) suppressed callus remodeling but did not interfere with fracture healing in rat femora. Bone 2007;40:132-9
   PubMed Web of Science ®Google Scholar
• Sakai S, Endo K, Takeda S, Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone 2012;50:1054-63
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Futaki N, Harada M, Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate. Bone 2013;52:181-8
   PubMed Web of Science ®Google Scholar
• Miyata K, Ohba Y, Abe M, Effects of eldecalcitol on the pharmacokinetics of the CYP3A4 substrate, simvastatin: double blind, randomized, placebo-controlled, parallel group comparative study in healthy male volunteers. Jpn Pharmacol Ther 2011;39:275-85
   Google Scholar
• Matsumoto T, Kubodera N. The ED-71 Study Group. 1alpha,25-Dihydroxy-2beta-(3-hydroxypropoxy) vitamin D3 (ED-71): a promising Candidate for the Treatment of Osteoporosis. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D endocrine system: structural, biological, genetic and clinical aspects. Vitamin D Workshop, Inc, University of California, Riverside; 2000. p. 985-92
   Google Scholar
• Matsumoto T, Miki T, Hagino H, A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005;90:5031-6
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Kubodera N. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 2007;103:584-6
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ito M, Hayashi Y, A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - a randomized, active comparator, double-blind study. Bone 2011;49:605-12
   PubMed Web of Science ®Google Scholar
• Hagino H. Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention–Post hoc analysis. Clin Calcium 2011;21:111-18
   PubMedGoogle Scholar
• Matsumoto T, Hagino H, Shiraki M, Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 2009;20:1429-37
   PubMed Web of Science ®Google Scholar
• Hagino H, Takano T, Fukunaga M, Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J Bone Miner Metab 2012; published online 6 November 2012; doi: 10.1007/s00774-012-0397-6
   Google Scholar
• Shiraki M, Saito H, Matsumoto T. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels. Curr Med Res Opin 2012;28:1547-52
   PubMed Web of Science ®Google Scholar
• Yoneda T, Hagino H, Sugimoto T, Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28:365-83
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;2267-94
   PubMed Web of Science ®Google Scholar